Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now
Executive Summary
Federal Circuit stays injunction that would have halted sales of the PCSK9 inhibitor on Feb. 21; stay extends through appeal of injunction and patent verdict.
You may also be interested in...
Praluent Lives On As US Court Vacates Amgen's PCSK9 Patent Win
While sales of Sanofi/Regeneron's Praluent, which will remain on the US market for the time being, could see a small boost, larger commercial challenges in the PCSK9 category linger.
Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal
Three-judge US federal appellate panel focuses on evidentiary rulings and patent validity in the dispute between Repatha marketer Amgen and Sanofi/Regeneron; lower court’s permanent injunction barring sales of Praluent did not come up at oral arguments.
PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches
After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.